Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 2/20 | 0.41 |
| ▸ | CPA1 | P15085 | 2/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.41 |
| ▸ | CPA3 | P15088 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL403254 | 0.81 | SLC7A5 (0.65) | — | |
| SCHEMBL21149890 | 0.81 | CTBP2 (0.47) | MMEFOLH1 | |
| SCHEMBL31453790 | 0.81 | SLC7A5 (0.65) | — | |
| SCHEMBL8470767 | 0.81 | PNMT (0.51) | MME | |
| SCHEMBL28939561 | 0.81 | MME (0.49) | MMEFOLH1 | |
| SCHEMBL403255 | 0.81 | SLC7A5 (0.65) | — | |
| SCHEMBL20298379 | 0.81 | SLC7A5 (0.65) | — | |
| SCHEMBL498453 | 0.81 | MME (0.65) | MMEFOLH1CYP1A2ACECPA1 | |
| SCHEMBL4838500 | 0.81 | MME (0.65) | MMEFOLH1CYP1A2ACECPA1 | |
| Hydrochloric Acid SCHEMBL7054010 | 0.79 | MME (0.62) | MMEFOLH1CYP1A2ACECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3138832-A1 | SUBSTITUTED PHENOXY- AND PHENYLTHIO- DERIVATIVES FOR TREATING PROLIFERATIVE DISORDERS | Temple University - Of The Commonwealth System of Higher Education (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-1740530-B1 | SUBSTITUTED PHENOXY- AND PHENYLTHIO-DERIVATIVES FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2016-09-28 | — | — | EP | disclosed |
| US-7932242-B2 | Anticancer agents; radiation and chemical resistance | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2011-04-26 | — | — | US | disclosed |
| US-20080058290-A1 | Substituted Phenoxy-and Phenylthio-Derivatives for Treating Proliferative Disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-03-06 | — | — | US | disclosed |
| EP-1740530-A4 | SUBSTITUTED PHENOXY- AND PHENYLTHIO- DERIVATIVES FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1740530-A2 | SUBSTITUTED PHENOXY- AND PHENYLTHIO- DERIVATIVES FOR TREATING PROLIFERATIVE DISORDERS | Temple University of the Commonwealth System of Higher Education (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005089269-A2 | SUBSTITUTED PHENOXY- AND PHENYLTHIO- DERIVATIVES FOR TREATING PROLIFERATIVE DISORDERS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058290-A1 | Substituted Phenoxy-and Phenylthio-Derivatives for Treating Proliferative Disorders | PCNA, MKI67, TP53 | MME 3210/4885FOLH1 1358/4885CYP1A2 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.